ArKal Medical

ArKal Medical was a medical device company specializing in the development of minimally invasive continuous glucose monitoring (CGM) technology. The company's core innovation centered on a microneedle-based dermal patch designed to measure glucose levels in the interstitial fluid with significantly less pain than conventional sensors. This technology aimed to improve patient compliance and quality of life for individuals managing diabetes. In 2011, ArKal Medical was acquired by Dexcom, a leader in the CGM market, to integrate its intellectual property and microneedle expertise into Dexcom's product roadmap. The acquisition was valued at approximately $14.2 million in initial cash consideration.